In the US, Ramucirumab (ramucirumab systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer and Stomach Cancer.
CAS registry number (Chemical Abstracts Service)
Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist
immunoglobulin G1-kappa, anti-[Homo sapiensvascular endothelial growth factor receptor 2 (VEGFR2,KDR,kinase insert domain receptor, FLK1,CD309) extracellular domain], Homo sapiensmonoclonal antibody; gamma1 haevy chain (1-446) [Homo sapiensVH (IGHV3-21*01 (WHO)
- Ramucirumabum (Latin)
- Ramucirumab (German)
- Ramucirumab (French)
- Ramucirumab (Spanish)
- Ramucirumab (OS: USAN)
- UNII-D99YVK4LOX (IS)
Eli Lilly, Switzerland; Eli Lilly, Croatia (Hrvatska); Eli Lilly, Ireland; Eli Lilly, Poland; Eli Lilly and Company, United Kingdom; Eli Lilly and Company, United States; Lilly, Germany; Lilly, France; Lilly, Slovenia; Lilly, Slovakia
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.